



BlueCross BlueShield
of Alabama

Name of Blue Advantage Policy:

Navigated Transcranial Magnetic Stimulation (nTMS)

Policy #: 556
Category: Medicine

Latest Review Date: July 2020
Policy Grade: C

BACKGROUND:

Blue Advantage medical policy does not conflict with Local Coverage Determinations (LCDs), Local Medical Review Policies (LMRPs) or National Coverage Determinations (NCDs) or with coverage provisions in Medicare manuals, instructions or operational policy letters. In order to be covered by Blue Advantage the service shall be reasonable and necessary under Title XVIII of the Social Security Act, Section 1862(a)(1)(A). The service is considered reasonable and necessary if it is determined that the service is:

1. *Safe and effective;*
2. *Not experimental or investigational*;*
3. *Appropriate, including duration and frequency that is considered appropriate for the service, in terms of whether it is:*
 - *Furnished in accordance with accepted standards of medical practice for the diagnosis or treatment of the patient's condition or to improve the function of a malformed body member;*
 - *Furnished in a setting appropriate to the patient's medical needs and condition;*
 - *Ordered and furnished by qualified personnel;*
 - *One that meets, but does not exceed, the patient's medical need; and*
 - *At least as beneficial as an existing and available medically appropriate alternative.*

Routine costs of qualifying clinical trial services with dates of service on or after September 19, 2000 which meet the requirements of the Clinical Trials NCD are considered reasonable and necessary by Medicare. Providers should bill **Original Medicare for covered services that are related to **clinical trials** that meet Medicare requirements (Refer to Medicare National Coverage Determinations Manual, Chapter 1, Section 310 and Medicare Claims Processing Manual Chapter 32, Sections 69.0-69.11).*

POLICY:

Effective for dates of service on and after May 16, 2014:

Blue Advantage will treat **navigated transcranial magnetic stimulation** as a **non-covered benefit** for all purposes, including but not limited to the preoperative evaluation of patients being considered for brain surgery, and is considered as **investigational**.

Blue Advantage does not approve or deny procedures, services, testing, or equipment for our members. Our decisions concern coverage only. The decision of whether or not to have a certain test, treatment or procedure is one made between the physician and his/her patient. Blue Advantage administers benefits based on the members' contract and medical policies. Physicians should always exercise their best medical judgment in providing the care they feel is most appropriate for their patients. Needed care should not be delayed or refused because of a coverage determination.

DESCRIPTION OF PROCEDURE OR SERVICE:

Navigated transcranial magnetic stimulation (nTMS) is a noninvasive imaging method for the evaluation of eloquent brain areas (e.g., controlling motor or language function). Navigated TMS is being evaluated as an alternative to other noninvasive cortical mapping techniques for presurgical identification of eloquent areas.

Management of Brain Tumors

Surgical management of brain tumors involves resecting the brain tumor and preserving essential brain function. “Mapping” of brain functions, such as body movement and language, is considered to be most accurately achieved with DCS, an intraoperative procedure that increases operating time and requires a wide surgical opening. Even if they are not completely accurate compared to DCS, preoperative techniques that map brain functions may aid in planning the extent of resection and the operative approach. Although DCS is still usually performed to confirm the brain locations associated with specific functions, preoperative mapping techniques may provide useful information that improves patient outcomes.

Noninvasive Mapping Techniques

The most commonly used tool for the noninvasive localization of brain functions is functional magnetic resonance imaging (fMRI). fMRI identifies regions of the brain where there are changes in localized cortical blood oxygenation, which correlates with the neuronal activity associated with a specific motor or speech task being performed as the image is obtained. The accuracy and precision of fMRI is dependent on the patient’s ability to perform the isolated motor task, such as moving the single assigned muscle without moving others. This may be difficult for patients in whom brain tumors have caused partial or complete paresis. The reliability of fMRI in mapping language areas has been questioned. Guissani et al (2010) reviewed several studies comparing fMRI and DCS of language areas and found large variability in sensitivity and specificity of fMRI. The discussion also points out a major conceptual point in how fMRI and DCS “map” language areas. fMRI findings reflect regional oxygenation changes, which show that a particular region of the brain is involved in the

capacity of interest, whereas DCS locates specific areas in which the activity of interest is disrupted. Regions of the brain involved in a certain activity may not necessarily be required for that activity and could theoretically be safely resected.

Magnetoencephalography (MEG) also is used to map brain activity. In this procedure, electromagnetic recorders are attached to the scalp. In contrast to electroencephalography, MEG records magnetic fields generated by electric currents in the brain, rather than the electric currents themselves. Magnetic fields tend to be less distorted by the skull and scalp than electric currents, yielding improved spatial resolution. MEG is conducted in a magnetically shielded room to screen out environmental electric or magnetic noise that could interfere with the MEG recording.

Navigated transcranial magnetic stimulation (nTMS) is a noninvasive imaging method for the evaluation of eloquent brain areas. Transcranial magnetic pulses are delivered to the patient as a navigation system calculates the strength, location, and direction of the stimulating magnetic field. The locations of these pulses are registered to a magnetic resonance imaging (MRI) image of the patient's brain. Surface electromyography (EMG) electrodes are attached to various limb muscles of the patient. Moving the magnetic stimulation source to various parts of the brain causes EMG electrodes to respond; indicating the part of the cortex involved in particular muscle movements. For evaluation of language areas, magnetic stimulation areas that disrupt specific speech tasks are thought to identify parts of the brain involved in speech function. nTMS can be considered a noninvasive alternative to DCS, in which electrodes are directly applied to the surface of the cortex during craniotomy. nTMS is being evaluated as an alternative to other noninvasive cortical mapping techniques, such as fMRI and MEG, for presurgical identification of cortical areas involved in motor and language functions. Navigated TMS, used for cortical language area mapping, is also being investigated in combination with diffusion tensor imaging tractography for subcortical white matter tract mapping.

KEY POINTS:

This policy was updated using references identified in the MEDLINE database through May 27, 2020.

Summary of Evidence

For individuals who have brain lesion(s) undergoing preoperative evaluation for localization of eloquent areas of the brain who receive nTMS, the evidence includes controlled observational studies and case series. Relevant outcomes are overall survival, test accuracy, morbid events, and functional outcomes. Several small studies have evaluated the distance between nTMS hotspots and direct cortical stimulation hotspots for the same muscle. Although the average distance in most studies is 10 mm or less, this does not take into account the error margin in this average distance or whether hotspots are missed. It is difficult to verify nTMS hotspots fully because only exposed cortical areas can be verified with direct cortical stimulation. Limited studies of nTMS evaluating language areas have shown high false-positive rates (low specificity) and sensitivity that may be insufficient for clinical use. Several controlled observational studies have compared outcomes in patients undergoing nTMS with those

(generally pre-TMS historical controls) who did not undergo nTMS. Findings of the studies were mixed; outcomes were not consistently better in patients who underwent presurgical nTMS. For example, overall survival did not differ significantly between groups in two studies and one reporting postoperative language deficits found significantly fewer deficits in the group that had presurgical nTMS. The controlled observational studies had various methodologic limitations and, being nonrandomized, might not have adequately controlled for differences in patient groups, which could have biased outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

Practice Guidelines and Position Statements

No guidelines or statements were identified.

U.S. Preventive Services Task Force Recommendations

Not applicable.

KEY WORDS:

Navigated transcranial magnetic stimulation, nTMS, Nexstim®, Nexstim NBS System 4, NexSpeech®

APPROVED BY GOVERNING BODIES:

In 2009, the eXimia Navigated Brain Stimulation System (Nexstim) was cleared for marketing by the U.S. Food and Drug Administration through the 510(k) process for noninvasive mapping of the primary motor cortex of the brain to its cortical gyrus for preprocedural planning.

Similarly, the Nexstim NBS System 4 and NBS System 4 with NexSpeech® received FDA 510(k) clearance in May 2012 for noninvasive mapping of the primary motor cortex and for localization of cortical areas that do not contain speech function, for the purposes of preprocedural planning.

BENEFIT APPLICATION:

Coverage is subject to member’s specific benefits. Group specific policy will supersede this policy when applicable.

CURRENT CODING:

CPT Codes:

As of 01/01/2018, there is no specific CPT code for this procedure. Use the following CPT code:

64999	Unlisted procedure, nervous system
--------------	------------------------------------

Previous Coding:

0310T	Motor function mapping using noninvasive navigated transcranial magnetic stimulation (nTMS) for therapeutic treatment planning, upper and lower extremity (Deleted 12/31/2017)
--------------	--

REFERENCES:

1. Conti A, Raffa G, Granata F, et al. Navigated Transcranial Magnetic Stimulation for "Somatotopic" Tractography of the Corticospinal Tract. *Neurosurgery*. Dec 2014; 10 Suppl 4:542-554.
2. Forster MT, Hattingen E, Senft C et al. Navigated transcranial magnetic stimulation and functional magnetic resonance imaging: advanced adjuncts in preoperative planning for central region tumors. *Neurosurgery* 2011; 68(5):1317-24; discussion 24-5.
3. Forster MT, Limbart M, Seifert V et al. Test-Retest-Reliability of Navigated Transcranial Magnetic Stimulation of the Motor Cortex. *Neurosurgery* 2013.
4. Frey D, Schilt S, Strack V, et al. Navigated transcranial magnetic stimulation improves the treatment outcome in patients with brain tumors in motor eloquent locations. *Neuro Oncol*. Oct 2014; 16(10):1365-1372.
5. Giussani C, Roux FE, Ojemann J et al. Is preoperative functional magnetic resonance imaging reliable for language areas mapping in brain tumor surgery? Review of language functional magnetic resonance imaging and direct cortical stimulation correlation studies. *Neurosurgery* 2010; 66(1):113-20.
6. Hendrix P, Senger S, Simgen A, et al. Preoperative rTMS language mapping in speech- eloquent brain lesions resected under general anesthesia: a pair-matched cohort study. *World Neurosurg*. Apr 2017; 100:425-433.
7. Jensen RL. Navigated transcranial magnetic stimulation: another tool for preoperative planning for patients with motor-eloquent brain tumors. *Neuro Oncol*. Oct 2014; 16(10):1299-1300.
8. Kato N, Schilt S, Schneider H, et al. Functional brain mapping of patients with arteriovenous malformations using navigated transcranial magnetic stimulation: first experience in ten patients. *Acta Neurochir (Wien)*. May 2014; 156(5):885-895.
9. Krieg SM, Sabih J, Bulubasova L, et al. Preoperative motor mapping by navigated transcranial magnetic brain stimulation improves outcome for motor eloquent lesions. *Neuro Oncol*. Sep 2014; 16(9):1274-1282.
10. Krieg SM, Shiban E, Buchmann N et al. Utility of presurgical navigated transcranial magnetic brain stimulation for the resection of tumors in eloquent motor areas. *J Neurosurg* 2012; 116(5):994-1001.
11. Krieg SM, Sollmann N, Hauck T, et al. Repeated mapping of cortical language sites by preoperative navigated transcranial magnetic stimulation compared to repeated intraoperative DCS mapping in awake craniotomy. *BMC Neurosci*. 2014; 15:20.
12. Krieg SM, Sollmann N, Obermueller T, et al. Changing the clinical course of glioma patients by preoperative motor mapping with navigated transcranial magnetic brain stimulation. *BMC Cancer*. 2015; 15:231.

13. Mangraviti A, Casali C, Cordella R et al. Practical assessment of preoperative functional mapping techniques: navigated transcranial magnetic stimulation and functional magnetic resonance imaging. *Neurol Sci* 2013; 34(9):1551-1557.
14. Nexstim. Healthcare providers: clinical evidence. www.nexstim.com/healthcare-providers/navigated-brain-stimulation/clinical-evidence/.
15. Opitz A, Zafar N, Bockermann V, et al. Validating computationally predicted TMS stimulation areas using direct electrical stimulation in patients with brain tumors near precentral regions. *Neuroimage Clin.* 2014; 4:500-507.
16. Paiva WS, Fonoff ET, Marcolin MA, et al. Navigated transcranial magnetic stimulation in preoperative planning for the treatment of motor area cavernous angiomas. *Neuropsychiatr Dis Treat.* 2013; 9:1885-1888.
17. Picht T. Current and potential utility of transcranial magnetic stimulation in the diagnostics before brain tumor surgery. *CNS Oncol.* Jul 2014; 3(4):299-310.
18. Picht T, Krieg SM, Sollmann N et al. A comparison of language mapping by preoperative navigated transcranial magnetic stimulation and direct cortical stimulation during awake surgery. *Neurosurgery* 2013; 72(5):808-19.
19. Picht T, Schmidt S, Brandt S, et al. Preoperative functional mapping for rolandic brain tumor surgery: comparison of navigated transcranial magnetic stimulation to direct cortical stimulation. *Neurosurgery.* Sep 2011;69(3):581-588; discussion 588.
20. Picht T, Schulz J, Hanna M et al. Assessment of the influence of navigated transcranial magnetic stimulation on surgical planning for tumors in or near the motor cortex. *Neurosurgery* 2012; 70(5):1248-56; discussion 1256-1247.
21. Rizzo V, Terranova C, Conti A, et al. Preoperative functional mapping for rolandic brain tumor surgery. *Neurosci Lett.* Sep 16 2014; 583C:136-141.
22. Schmidt S, Bathe-Peters R, Fleischmann R, et al. Nonphysiological factors in navigated TMS studies; Confounding covariates and valid intracortical estimates. *Hum Brain Mapp.* Aug 29 2014.
23. Sollmann N, Hauck T, Hapfelmeier A, et al. Intra- and interobserver variability of language mapping by navigated transcranial magnetic brain stimulation. *BMC Neurosci.* 2013; 14:150.
24. Sollmann N, Ille S, Boeckh-Behrens T, et al. Mapping of cortical language function by functional magnetic resonance imaging and repetitive navigated transcranial magnetic stimulation in 40 healthy subjects. *Acta Neurochir (Wien).* May 2 2016.
25. Sollmann N, Ille S, Hauck T, et al. The impact of preoperative language mapping by repetitive navigated transcranial magnetic stimulation on the clinical course of brain tumor patients. *BMC Cancer.* 2015; 15:261.
26. Sollmann N, Tanigawa N, Tussis L, et al. Cortical regions involved in semantic processing investigated by repetitive navigated transcranial magnetic stimulation and object naming. *Neuropsychologia.* Apr 2015; 70:185-195.
27. Tarapore PE, Findlay AM, Honma SM et al. Language mapping with navigated repetitive TMS: Proof of technique and validation. *Neuroimage* 2013; 82:260-72.
28. Tarapore PE, Picht T, Bulubas L, et al. Safety and tolerability of navigated TMS for preoperative mapping in neurosurgical patients. *Clin Neurophysiol.* Mar

- 2016; 127(3):1895-1900.
29. Tarapore PE, Tate MC, Findlay AM et al. Preoperative multimodal motor mapping: a comparison of magnetoencephalography imaging, navigated transcranial magnetic stimulation, and direct cortical stimulation. *J Neurosurg* 2012; 117(2):354-62.
 30. Weiss C, Nettekoven C, Rehme AK et al. Mapping the hand, foot, and face representations in the primary motor cortex-- retest reliability of neuronavigated TMS versus functional MRI. *Neuroimage* 2013; 66:531-542.

POLICY HISTORY:

Adopted for Blue Advantage, April 2014

Available for comment April 1 through May 15, 2014

Medical Policy Group, February 2015

Medical Policy Group, July 2016

Medical Policy Group, June 2017

Medical Policy Group, December 2017

Medical Policy Group, June 2018

Medical Policy Group, December 2018

Medical Policy Group, July 2019

Medical Policy Group, July 2020

This medical policy is not an authorization, certification, explanation of benefits, or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member's plan in effect as of the date services are rendered. All medical policies are based on (i) research of current medical literature and (ii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment.

This policy is intended to be used for adjudication of claims (including pre-admission certification, pre-determinations, and pre-procedure review) in Blue Cross and Blue Shield's administration of plan contracts.